Back to Agenda
COHORT STUDIES OF THE ELDERLY AS A TOOL FOR DRUG DEVELOPMENT AND TESTING
Session Chair(s)
Markus Georg Pasterk, MS
COO and Vice President Science
IPRI, France
Large-scale longitudinal studies are ongoing in many countries, which include elderly populations. These studies typically comprise a good assessment of comorbidities and other risk factors, as well as prospective outcome assessment. They represent a potentially useful tool to develop ad hoc projects for drug development and testing. The overarching goal of the session will be to offer a discussion forum on the possible use of large-scale observational studies for drug development and testing studies. The session will comprise a presentation of a large consortium of prospective studies of elderly in Europe and North America (the CHANCES Consortium), a discussion of the advantages and limitations of observational studies for drug development, and a critical assessment of the important of pharmacologic interventions in healthy aging.
Speaker(s)
Opportunities in the CHANCES Consortium
Paolo Boffetta, MD, MPH
Mount Sinai School of Medicine, United States
Director Institute of Translational Epidemiology
Drug Development in Dementia Disease - The interplay of observational studies and experimental interventions studies
Sture Eriksson
University of Umea, Sweden
Biobanking as a Tool for Drug Development within Special Populations
Kurt Zatloukal
Medical University Graz, Austria
Professor of Pathology
Have an account?